AbbVie Reports Global Resolution Of HUMIRA Patent Disputes With Samsung Bioepis; Deal Provides Non-Exclusive License To Samsung Bioepis For HUMIRA-Related IP In US, Effective Jun. 30, Other Markets On Diff. Dates